panitumumab
- Generic Name
- panitumumab
- Brand Names
- Vectibix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 339177-26-3
- Unique Ingredient Identifier
- 6A901E312A
- Background
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.
- Indication
美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。
- Associated Conditions
- Metastatic Colorectal Cancer (CRC)
- Associated Therapies
- -
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT01916109
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer
- First Posted Date
- 2013-03-01
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 52
- Registration Number
- NCT01801904
- Locations
- 🇮🇹
A.O.U. Policlinico Federico II, Napoli, Italy
🇮🇹Istituto Nazionale dei Tumori, Napoli, Italy
🇮🇹Azienda Ospedaliera G. Rummo, Benevento, BN, Italy
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT01776307
- Locations
- 🇺🇸
USOR - Texas Oncology Tyler, Tyler, Texas, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸US Oncology Research, The Woodlands, Texas, United States
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
- Conditions
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 166
- Registration Number
- NCT01750918
- Locations
- 🇬🇧
Novartis Investigative Site, Birmingham, United Kingdom
Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2017-08-01
- Target Recruit Count
- 72
- Registration Number
- NCT01704703
- Locations
- 🇪🇸
Spanish Cooperative Group for Digestive Tumour Therapy, Madrid, Spain
Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2018-03-02
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 300
- Registration Number
- NCT01627379
- Locations
- 🇩🇪
Johannes-Gutenberg-Universität Mainz, I. Medizinische Klinik und Poliklinik, Mainz, Rheinland-Pfalz, Germany
P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 22
- Registration Number
- NCT01591421
- Locations
- 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
🇨🇦Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
- Conditions
- Interventions
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 45
- Registration Number
- NCT01581840
- Locations
- 🇫🇷
Clinique Privée - Plein Ciel, Mougins, France
🇫🇷Pessac - Hôpital Haut Lévêque, Bordeaux, France
🇫🇷Centre d'oncologie et de radiothérapie du Parc, Dijon, France
MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2011-09-29
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 162
- Registration Number
- NCT01443065
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment
- Conditions
- Interventions
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2014-07-14
- Target Recruit Count
- 11
- Registration Number
- NCT01418742
- Locations
- 🇩🇪
Onkologische Schwerpunktpraxis, Brandenburg, Germany
🇩🇪Medizinisches Versorgungszentrum Ärzteforum Seestraße, Berlin, Germany
🇩🇪Ärzteforum Bernau, Bernau, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.